POST STROKE BRAIN RECOVERY TARGETING BLOOD FLOW AND VESSEL HEALTH
Dr Daniel Beard,
Senior Lecturer, University of Newcastle
Group Leader, Neurovascular Research Laboratory
New South Wales, Australia &
Visiting Scientist,
University of Oxford, United Kingdom &
Founder and Chief Scientific Officer
ShearFlow
RESEARCHER PROFILE
Filmed in Newcastle, Australia | May 2026
Dr Daniel Beard is a Senior Lecturer and Group Leader of the Neurovascular Research Laboratory at the University of Newcastle, with a distinguished career in stroke research. Dr Beard completed his PhD in Human Physiology in 2015, uncovering the impact of intracranial pressure on collateral vessel failure. He has held prestigious research and teaching roles at the University of Oxford and Charité Universitätsmedizin Berlin, contributing to international collaborations on neurovascular protection. His research has been supported by competitive grants, including an NHMRC Ideas Grant, and he has received numerous awards for innovation, research excellence and teaching excellence, including:
-Winner of the Challenger Pitch Prize at the Proto Axiom Challenger Summit (2024).
-Paul Dudley White International Scholar for the highest-ranked Australian abstract at the 2022 International Stroke Conference, New Orleans.
-Recipient of the Learning Design and Teaching Innovation Teaching Excellence Award and Mid-Career Teaching Award from the University of Newcastle (2024).
His most recent work focuses on understanding and improving collateral blood flow during ischaemic stroke. Notably, his groundbreaking work on shear stress and cerebral blood flow with renowned researchers at Harvard University, resulted in a patented nanoparticle therapy that selectively boosts brain perfusion during stroke, saving brain tissue and improving patient outcomes. This work was recently published in Advanced Science: https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202506276.
Dr Beard is Founder and Chief Scientific Officer of the University spinout ShearFlow that is now commercializing this technology to reach the clinic. This work aims to deliver targeted stroke therapies that could give patients a improved chance at recovery and a better quality of life.
Source: Supplied and adapted
https://orcid.org/0000-0002-3720-7588
-
Biomarkers for early sepsis detection
Dr Gabrielle Briggs is a biomedical scientist dedicated to finding smarter, faster ways to diagnose and treat life threatening complications in critically ill patients. Dr Briggs established a research laboratory embedded within the John Hunter Hospital – one of the busiest major trauma centres in NSW. Dr Briggs works alongside surgeons, intensivists, and pathologists to turn complex clinical problems into practical research solutions. Her work spans two major programs: developing a rapid diagnostic test to detect bacterial infections in blood before sepsis takes hold, and exploring mitochondrial transplantation as a novel therapy to rescue injured tissues after trauma and ischaemia.
-
Exercise therapy for metabolic dysfunction-associated steatotic liver disease
Dr Shelley Keating is a Senior Lecturer in Clinical Exercise Physiology and Accredited Exercise Physiologist from the School of Human Movement and Nutrition Sciences at the University of Queensland. With a strong grounding in exercise metabolism and body composition, Dr Keating’s research centres on the utility of exercise as a therapy for obesity and related cardiometabolic conditions, notably metabolic dysfunction-associated steatotic liver disease (MASLD).
-
Novel therapy for pancreatic cancers, targeting molecular foundation
Dr Michael Lee is an experienced medical oncologist, sub-specialising in gastrointestinal cancers and neuroendocrine tumours at the Peter MacCallum Cancer Centre.
He plays a key role in molecular tumour boards at VCCC Alliance (Victorian Comprehensive Cancer Centre) and MPCCC (Monash Partners Comprehensive Cancer Consortium), ensuring the accurate and effective use of precision medicine in cancer care across the state.
